Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of the efficacy of immunotherapy by measuring the integrity of cell‐free DNA in plasma in colorectal cancer

24 Sept 2016

Abstract excerpt

We previously reported a phase II study of a cancer vaccine using five novel peptides recognized by HLA-A*2402-restricted CTL in combination with oxaliplatin-containing chemotherapy (FXV study) as first-line therapy for patients with metastatic colorectal cancer and demonstrated the safety and promising potential of our five-peptide cocktail. The objective of this analysis was to identify predictive biomarkers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27663862
DOI: 10.1111/cas.13085

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of the efficacy of immunotherapy by measuring the integrity of cell‐free DNA in plasma in colorectal cancerPMID 27663862Read ↗

Detection and Monitoring of Cell‐Free DNA in Blood of Patients with Colorectal CancerSemantic proximity Read ↗

Clinical utility of circulating cell-free DNA in advanced colorectal cancer.Semantic proximity Read ↗

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatmentSemantic proximity Read ↗

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.Semantic proximity Read ↗

The Importance of Feasibility Assessment in the Design of ctDNA Guided Trials - Results From the OPTIPAL II Study.Semantic proximity Read ↗

Recent Advances in Clinical Applications of Circulating Cell-free DNA Integrity: Table 1Semantic proximity Read ↗

The kinetics and fragmentation of cell-free DNA from cultured cancer cells are influenced by anticancer treatmentsSemantic proximity Read ↗

Cell-free DNA concentration and integrity as a screening tool for cancerSemantic proximity Read ↗

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.Semantic proximity Read ↗

Diagnostic and Prognostic Value of Circulating DNA Fragments in Glioblastoma Multiforme PatientsSemantic proximity Read ↗

The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Increased Free Circulating DNA Integrity Index as a Serum Biomarker in Patients with Colorectal CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.